A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance StudyEvaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis
A study for patients with moderate to severe Ulcerative Colitis using study drug GS-5745
Sponsor: Gilead
Enrolling: Male and Female Patients
IRB Number: AAAP8919
U.S. Govt. ID: NCT02520284
Contact: Tanjina Razzaque: 212-342-1464 / tr2432@columbia.edu
Additional Study Information: The purpose of this study is to see how safe and effective study drug GS-5745 is in treating people with moderate to severe Ulcerative Colitis. This is a randomized, double-blind, placebo-controlled study. Placebo-controlled means that you may receive an injection with no medicine in it, but looks like GS-5745. Randomized means you will be selected by chance (like flipping a coin) to receive either one of three treatments which will be administered in weekly injections. If you are eligible to take part in Group 1 of this study, you will be randomized and will have a one in three chance of receiving one of the following treatments: 150 mg GS-5745, 150 mg GS-5745 and placebo, switching each week or Placebo.
This study is closed
Simon Lichtiger, MD
Do You Qualify?
Do you have Ulcerative Colitis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Tanjina Razzaque